Ge Long Hui·2026-02-24 08:39Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing of rivaroxaban tablets produced by its subsidiary, Changzhou Pharmaceutical Factory [1] Group 1: Product Information - Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat and prevent deep vein thrombosis (DVT), treat pulmonary embolism (PE), and prevent venous thromboembolism (VTE) in acutely ill patients [1] - The drug was originally co-developed by BAYER and JANSSEN and was first launched in the United States in 2011 [1] Group 2: Regulatory Approvals - The rivaroxaban tablets received approval from the U.S. Food and Drug Administration (FDA) in May 2025 and obtained a drug registration certificate in Malaysia in October 2025 [1] Group 3: Investment and R&D - As of the date of the announcement, the company has invested approximately RMB 3.2482 million in research and development for the drug's market entry in Southeast Asia, including Thailand, Singapore, Malaysia, and the Philippines [1]